PanTher Therapeutics

PanTher Therapeutics is a clinical-stage oncology company dedicated to improving cancer treatment. The company develops innovative therapeutics that deliver cancer-fighting drugs directly to tumor sites, enhancing clinical outcomes while reducing systemic side effects. Their proprietary Sagittari™ platform allows for optimized drug products that achieve over 100 times higher drug concentration at the tumor compared to traditional systemic administration.

Led by CEO and Co-Founder Laura Indolfi, PanTher's team includes experts in oncology and drug development. The company's key candidates include PTM-101, currently in a Phase 1b clinical study for locally advanced pancreatic adenocarcinoma, and PTM-201, which is in the preclinical stage for solid tumors. PanTher's approach focuses on localized drug delivery, aiming to maximize the effectiveness of treatments while minimizing exposure to the rest of the body.